Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -37.05% is in line with its 4-year average of -37.74%, around the middle of its 4-year range (-59.74%–-22.17%).
As of the fiscal period ended Wednesday, December 31, 2025. 7.83% below its 12-month average of -34.36%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -32.13%.
RETURN ON ASSETS (ROA)
-37.05%
RETURN ON ASSETS (ROA) AVG TTM
-34.36%
RETURN ON ASSETS (ROA) AVG 3Y
-41.63%
RETURN ON ASSETS (ROA) AVG 5Y
-37.74%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-7.83%
CURRENT VS 3Y AVG
+11.00%
CURRENT VS 5Y AVG
+1.82%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.37%
median of 781 covered companies
CURRENT VS SECTOR MEDIAN
-18.11%
vs the sector median at left
Boundless Bio, Inc.
Market Cap
$57.42M
Return on Assets (ROA)
-37.05%
TTM Avg
-34.36%
3Y Avg
-41.63%
5Y Avg
-37.74%
Market Cap
$58.44M
Return on Assets (ROA)
-382.32%
TTM Avg
-98.02%
3Y Avg
-80.35%
5Y Avg
-65.77%
Market Cap
$58.50M
Return on Assets (ROA)
-128.88%
TTM Avg
-89.84%
3Y Avg
-89.26%
5Y Avg
-80.42%
Market Cap
$56.78M
Return on Assets (ROA)
-42.67%
TTM Avg
-85.33%
3Y Avg
-379.34%
5Y Avg
-281.82%
Market Cap
$58.79M
Return on Assets (ROA)
-118.15%
TTM Avg
-138.13%
3Y Avg
-224.99%
5Y Avg
-221.92%
Market Cap
$59.91M
Return on Assets (ROA)
-393.68%
TTM Avg
-194.68%
3Y Avg
-123.06%
5Y Avg
-102.52%
Market Cap
$60.07M
Return on Assets (ROA)
-98.94%
TTM Avg
-57.19%
3Y Avg
-57.75%
5Y Avg
-128.29%
Market Cap
$60.48M
Return on Assets (ROA)
-66.80%
TTM Avg
-56.95%
3Y Avg
-50.95%
5Y Avg
-40.99%
Market Cap
$60.49M
Return on Assets (ROA)
-14.15%
TTM Avg
-52.30%
3Y Avg
-73.34%
5Y Avg
-79.94%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Boundless Bio, Inc. (BOLD) | $57.42M | -37.05% | -34.36% | -41.63% | -37.74% |
| PDS Biotechnology Corporation (PDSB)vs › | $58.44M | -382.32% | -98.02% | -80.35% | -65.77% |
| Fractyl Health, Inc. (GUTS)vs › | $58.50M | -128.88% | -89.84% | -89.26% | -80.42% |
| OKYO Pharma Limited (OKYO)vs › | $56.78M | -42.67% | -85.33% | -379.34% | -281.82% |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.79M | -118.15% | -138.13% | -224.99% | -221.92% |
| Oncolytics Biotech Inc. (ONCY)vs › | $59.91M | -393.68% | -194.68% | -123.06% | -102.52% |
| Connect Biopharma Holdings Limited (CNTB)vs › | $60.07M | -98.94% | -57.19% | -57.75% | -128.29% |
| Adicet Bio, Inc. (ACET)vs › | $60.48M | -66.80% | -56.95% | -50.95% | -40.99% |
| Xilio Therapeutics, Inc. (XLO)vs › | $60.49M | -14.15% | -52.30% | -73.34% | -79.94% |
| Kalaris Therapeutics Inc (KLRS)vs › | $61.77M | -44.47% | -42.63% | -230.85% | -167.04% |
ROA
-37.0%
ROE
-59.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -37.05% |
| 2024-12-31 | -31.67% |
| 2023-12-31 | -38.06% |
| 2022-12-31 | -59.74% |
| 2021-12-31 | -22.17% |
| 2018-12-31 | -27.26% |
| 2017-12-31 | -50.51% |
| 2016-12-31 | -42.00% |
